Company Patenting Tech for Designing Babies
By John Fowler,
KTVU
| 11. 20. 2013
[With CGS's Marcy Darnovsky]
BERKELEY, Calif. — Parents will do just about anything to improve what they see as their children’s chance for success. But does that mean biotechnology?
Some say boosting a child’s chances before conception is ‘creepy’.
But what is wrong with a more perfect baby? One where you pick the eye color, athletic ability and disease risk?
“I guess if you could eliminate that (disease risk) that’s a pretty good thing,” said Tom Robarge of San Francisco.
Though Narkee Rosenberg said “it’s a little like playing with fate and future, and I don’t know how I feel 100 percent about that”.
Biotechnology may now give parents unprecedented choices.
“Our understanding of genetics in the last ten years has really exploded,” said 23andme scientist Emily Conley.
Fertility clinics already use pre-implantation genetic diagnosis, PGD, to select traits for some in-vitro babies. But intentional manipulation might create ethical nightmares such as in the sci-fi film GATTACA where genetics means success.
Marcy Darnovsky from the Center for Genetics and Society in Berkeley is very concerned of this possibility.
“A world of genetic haves and...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...